Vaxart (NASDAQ:VXRT) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Vaxart (NASDAQ:VXRT – Get Rating) announced its earnings results on Monday. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04), MarketWatch Earnings reports. Vaxart had a negative net margin of 7,900.22% and a negative return on equity of 36.68%.

VXRT opened at $3.16 on Tuesday. The firm has a market cap of $399.44 million, a P/E ratio of -5.45 and a beta of 0.67. Vaxart has a 1-year low of $3.11 and a 1-year high of $10.33. The company has a 50 day simple moving average of $4.54 and a two-hundred day simple moving average of $5.53.

Separately, Zacks Investment Research raised shares of Vaxart from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Vaxart currently has a consensus rating of “Buy” and an average price target of $12.10.

Several large investors have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Vaxart by 29.6% during the fourth quarter. State Street Corp now owns 11,187,642 shares of the biotechnology company’s stock worth $70,147,000 after acquiring an additional 2,554,787 shares during the last quarter. BlackRock Inc. lifted its position in Vaxart by 4.4% during the fourth quarter. BlackRock Inc. now owns 8,452,420 shares of the biotechnology company’s stock valued at $52,997,000 after purchasing an additional 357,036 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Vaxart by 4.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 886,413 shares of the biotechnology company’s stock valued at $5,558,000 after purchasing an additional 40,405 shares during the last quarter. UBS Group AG lifted its position in Vaxart by 1,668.9% during the third quarter. UBS Group AG now owns 430,119 shares of the biotechnology company’s stock valued at $3,419,000 after purchasing an additional 405,804 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Vaxart by 10.0% during the third quarter. Bank of New York Mellon Corp now owns 423,665 shares of the biotechnology company’s stock valued at $3,368,000 after purchasing an additional 38,682 shares during the last quarter. Hedge funds and other institutional investors own 45.91% of the company’s stock.

Vaxart Company Profile (Get Rating)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

Read More